Affiliations: [a] Consultant in Rehabilitation Medicine, Wrightington, Wigan and Leigh NHS Foundation Trust, Wigan, UK | [b] Specialist Registrar in Rehabilitation Medicine, Hope Hospital, Salford, UK | [c] Consultant in Rehabilitation Medicine, Preston Neurological Rehabilitation Unit, Preston, UK | [d] Consultant in Rehabilitation Medicine, Northern General Hospital, Sheffield, UK | [e] Specialist Registrar in Rehabilitation Medicine, Walkergate Park Centre for Neurorehabilitation, Newcastle, UK | [f] Consultant in Rehabilitation Medicine, Walkergate Park Centre for Neurorehabilitation, Newcastle, UK
Correspondence:
[*]
Corresponding author: Dr. Tarek A.-Z.K. Gaber, Consultant in Rehabilitation Medicine, Wrightington, Wigan and Leigh NHS Foundation Trust, Wigan WN7 1HS, UK. Tel.: +44 1942 264078; Fax: +44 1942 264517; E-mail: tgaber@doctors.net.uk
Abstract: Introduction:Hyperextension of the extensor hallucis longus (EHL) muscle is a well recognised disabling sequel of either pyramidal or extrapyramidal lesions causing what is known as striated or hitchhiker’s toe. Surgery was the only effective strategy to manage EHL hyperextension before botulinum toxin’s use to manage muscular dystonia and spasticity became widely popular. Methods:A multicentre retrospective study. A standard proforma was sent to specialists in neurological rehabilitation dealing routinely with this problem. The data was analysed using descriptive statistics. Results:Four consultants and two trainees representing five separate neurological rehabilitation services agreed to participate in the study. Full data was available from the 29 proformas completed. The subjects were 15 females with an age range between 20 and 78 years (mean 58.7). Stroke was the primary diagnosis in 18 subjects. Four subjects had bilateral involvement. 16 subjects had either an associated foot drop or equino varus deformity.Dysport® was used in 15 subjects with an average dose of 170 units per injection and Botox® in the other 14 with an average dose of 65 units. The treatment was effective in 24 subjects (83%). All patients receiving Dysport® responded to the treatment. Whilst 5 Botox® treated patients failed to respond to it (35% failure rate). Most of the non respondents seemed to receive insufficient doses of Botox® (below 60 units). Surgical management was successful in 3 out of the 5 non respondent cases. Conclusion:Botilinum Toxin is an effective and safe method to manage hitchhicker’s toe. In our study the conversion ratio between Dysport® and Botox® was 2.5:1. Third of the patients receiving Botox® failed to respond to the treatment most probably due to insufficient doses used.
